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Abstract. A rapid, on-bead enzyme-linked immunosorbent assay forPlasmodium lactate dehydrogenase (pLDH) and
Plasmodium falciparum histidine-rich protein 2 (HRP2) was adapted for use with dried blood spot (DBS) samples. This
assay detected both biomarkers from a single DBS sample with only 45 minutes of total incubation time and detection
limits of 600 ± 500 pM (pLDH) and 69 ± 30 pM (HRP2), corresponding to 150 and 24 parasites/μL, respectively. This
sensitive and reproducible on-beaddetectionmethodwas used to quantifypLDHandHRP2 in patient DBS samples from
rural Zambia collected at multiple time points after treatment. Biomarker clearance patterns relative to parasite clearance
weredetermined;pLDHclearance followedcloselywith parasite clearance,whereasmost patientsmaintaineddetectable
levels of HRP2 for 35–52 days after treatment. Furthermore, weak-to-moderate correlations between biomarker con-
centration and parasite densities were found for both biomarkers. This work demonstrates the utility of the developed
assay for epidemiological study and surveillance of malaria.
INTRODUCTION
Quantitative laboratory measurement of malarial protein
biomarkers helps define disease prevalence, distribution, and
infection intensities. In the context of malaria elimination,
sensitive detection methods are useful for determining re-
sponse to interventions on a population level, ensuring that
low-density infections are identified, and informing the de-
velopment of improved point-of-care diagnostics. However,
the logistics and biohazard risk of venouswhole blood sample
collection, preservation, and transportation from the field to
the laboratory often pose challenges to large studies.
Many of these challenges are mitigated by the use of dried
blood spot (DBS) cards for sample collection and preservation.
In this sampling technique, which does not require specialized
skills or equipment, microliter volumes of whole blood collected
fromafingerprickarespottedontofilterpapercardsandallowed
to dry at room temperature. These DBS samples are then easily
stored or shipped, pose little biohazard risk, and result in im-
proved biomarker stability compared with liquid samples.1,2 The
DBScardsareoften cost-effective comparedwith venouswhole
blood sample tubes and require no instrumentation to carry out
the minimally invasive collection procedure.3
Because of these advantages, DBS sample cards have
been used extensively in surveillance and epidemiological
studies of malaria. For example, extraction and detection/
sequencing of nucleic acid material from DBS have allowed
for not only malaria detection in symptomatic and asymp-
tomatic patients4–6 but also speciation,7 determination of
parasite diversity,8 identification of drug-resistant strains,9,10
and evaluation of rapid diagnostic tests on a population
level.11–13 Dried blood spots have also been used for the de-
tection of antimalarial antibodies for serology-based epide-
miological studies.14
Quantitation of malarial protein biomarkers from DBS
samples, although less common than nucleic acid detection,
is also relevant in the context of malaria elimination. Recently,
two studies havemeasured Plasmodium falciparum histidine-
rich protein 2 (HRP2), the primary protein biomarker used to
diagnosemalaria, in DBSpatient samples. Rogier et al.15 used
their DBS detection method to evaluate the accuracy of
HRP2-based rapid diagnostic tests, and Gibson et al.16
demonstrated the persistence of HRP2 in patient DBS sam-
ples after treatment compared with microscopy. Although
both of these studies demonstrated sensitive HRP2 quanti-
tation from DBS, there are several disadvantages of using
HRP2 alone as a diagnostic marker for malaria. First, HRP2
persists in host circulation for several weeks after parasite
clearance, potentially resulting in false-positive results and
unnecessary prescription of antimalarials.17 Second, HRP2 is
only expressed by one of the five species of malaria known to
infect humans. Third, infections with P. falciparum histidine-
rich protein 2 (pfhrp2) gene deletions are increasing in preva-
lence and result in false-negative results on HRP2-only tests,
posing a major challenge for case management.18
To address these disadvantages, we previously developed a
highly sensitive, magnetic bead–based assay that simulta-
neously captured and sequentially detected Plasmodium lac-
tate dehydrogenase (pLDH) and HRP2 from a single whole
bloodsample.19BecausepLDH isametabolic enzyme required
for parasite survival, it is present during infections from any of
the five species of malaria known to infect humans.20,21 In ad-
dition, pLDH has been shown to clear within days after treat-
ment.22 As such, this simultaneous capture and sequential
detection (SCSD) assay not only distinguishes between falci-
parum and non-falciparum infections but also differentiates
between active and resolved falciparum infections. In addition,
the lower limit of detection of the SCSD assay, 2.0 parasites/μL
for both pLDH andHRP2, was an order ofmagnitude improved
over commercially available enzyme-linked immunosorbent
assay (ELISA) kits and would allow for detection of individuals
with asymptomatic or submicroscopic malaria infections.19
In this work, we adapt the previously developed SCSD as-
say for pLDH and HRP2 to detect these biomarkers from DBS
and apply it to patient samples from rural Zambia. In particular,
the clearance patterns of both biomarkers relative to parasite
* Address correspondence to David W. Wright, Department of
Chemistry, Vanderbilt University, Nashville, TN 37235. E-mail: david.
wright@vanderbilt.edu
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clearance are investigated. The high sensitivity of this assay is
ideal for DBS sample analysis because these samples consist
of just a few microliters of whole blood diluted into extraction
buffer. In addition, the total protocol requires only 45 minutes
of total incubation time for quantitation of both biomarkers,
increasing the throughput and information yield per sample.
MATERIALS AND METHODS
Materials. Human whole blood (K3 EDTA) was purchased
from BioreclamationIVT (Hicksville, NY) (catalog no.
HMWBEDTA3). Recombinant HRP2 protein was gener-
ously provided by PATH (Seattle, WA). Recombinant
P. falciparum lactate dehydrogenase (rcPfLDH) was pur-
chased from CTK Biotech (San Diego, CA) (Catalog no.
A3005). Plasmodium falciparum D6 strain was cultured in
the laboratory (stock concentration 18,450 parasites/μL or
43,600 parasites/μL). Anti-HRP2 antibodies were purchased
from Abcam (Cambridge, United Kingdom) (ab9203, ab9206,
and ab30384). Anti-pLDH antibodies were purchased from
Vista Diagnostics (Kirkland, WA) (19g7 and 1201). Vista 1201
was conjugated to alkaline phosphatase (1201:AP) using
Abcamab102850and tohorseradishperoxidase (1201:HRPx)
using Thermo no. 31489. BluePhos® microwell phosphatase
substrate was purchased from KPL (Gaithersburg, MD) (No.
50-88-02), and TMB One was purchased from Promega (Madi-
son, WI) (G7431). Dynabeads® MyOne™ streptavidin T1 beads
were purchased from Life Technologies (Carlsbad, CA) (no.
65601). Immulon 2HBELISA plates (14-245-61) were purchased
from Fisher Scientific (Pittsburgh, PA). 903 Protein saver cards
were purchased from GE Healthcare Life Sciences (Marl-
borough, MA) (10534612). Six-millimeter biopunches were
acquired fromTedPella Inc. (Redding, CA) (catalog no. 15111-
60). All other reagents were purchased from either Fisher
Scientific or Sigma Aldrich (St. Louis, MO). Dried blood spot
extraction was performed with a Fisher Scientific analog
vortexmixer (02-215-365). Absorbancemeasurements were
collected on a Biotek Synergy H4 microplate reader (Van-
derbilt University) or Biotek ELx808 microplate reader
(Macha Research Trust).
Standardization of D6 P. falciparum culture. Two stocks
of in-house D6 P. falciparum culture (18,450 parasites/μL
and 43,600 parasites/μL) were used in this study. The pLDH
and HRP2 concentrations in the 18,450 parasite/μL stock
were previously reported as 1.3 and 1.7 pM per parasite/μL,
respectively.16,19 In addition, HRP2 in the 43,600 parasites/μL
stockwas previously determined to be 2.2 pMper parasite/μL.23
The pLDH concentration of in-house D6 P. falciparum cul-
ture (stock 43,600 parasites/μL) was determined to be 4.4 pM
per parasite/μL using a standard well-plate ELISA, N = 6
(Supplemental Text 1).
Dried blood spot preparation and extraction.Dried blood
spot extraction was adapted from a previously reported
method.16Driedblood spotwaspreparedbydepositing 10μLof
parasitized whole blood ontoWhatman 903 protein saver cards.
The spots were allowed to air-dry for a minimum of 4 hours,
removed using a 6-mm biopsy punch, and placed in 2-mL
microcentrifuge tubes (one spot per tube). Next, 200 μL of
phosphate-buffered saline (PBS) with 0.1% Tween-20 (PBST)
was added to each tube. The tubes were vortexed at 3,200 rpm
for 10 minutes and then placed in a mini-centrifuge for 30–60
seconds. The supernatant was removed and saved for analysis.
Bead preparation. Anti-pLDH and anti-HRP2 beads were
prepared as reported previously.19,24 Briefly, anti-pLDH (Vista
19g7) or anti-HRP2 (Abcam ab9203) was biotinylated with
EZ-Link NHS–PEG4–Biotin, No-Weigh Format (Thermo no.
21329). Unreacted NHS–PEG4–Biotin was removed using 7K
MWCO Zebra spin desalting columns (Thermo no. 89882).
Next, 5 mg of DynabeadsMyOne streptavidin T1 waswashed
three times with PBS and incubated with 500 μL of 0.4 mg/mL
biotinylated antibody in PBS for 30 minutes. The beads were
then washed before incubating in excess D-biotin in PBS
for 30 minutes. Finally, the beads were washed and resus-
pended in 500 μL of PBS with 0.01% Tween-20. Stock
solutions of antibody-functionalized beads were transported
to Zambia in ambient conditions and stored at 4C on arrival.
Simultaneous capture and sequential detection ELISA
with DBS extracts. The SCSD ELISA on DBS extracts was
adapted from the previously reported method.19 To avoid
bead aggregation, a low-resource–filtering method was de-
vised for removing small fibers and paper pieces from DBS
extracts (Figure 1). Nylon fabric (Walmart, Bentonville, AK, No
Nonsense Knee Highs) was cut to the appropriate size and
taped onto a Fisherbrand flat-bottom PS 96-well plate (no.
12565501). A polymerase chain reaction (PCR) plate with the
bottoms of the wells removed was then taped on top of
the flat-bottomplate such that the nylon fabricwas taut across
the bottom of each well, forming a nylon filter between the
wells of the flat-bottom and PCR plates. Next, 100 μL of DBS
extract was pipetted through the nylon fabric filter into the flat-
bottom plate. The nylon fabric and PCR plate were removed,
and 100 μL of 10% nonfat dried milk in PBST was added to
each well, followed by 4 μL of HAMA blocking reagent (Fitz-
gerald 85R-1001), 10 μL of 19g7-conjugatedmagnetic beads,
5 μL of ab9203-conjugated magnetic beads, 1.57 μL of 1201:
AP (1.27 mg/mL), and 2 μL of ab30384 (0.1 mg/mL). The plate
wasprotected from light and incubatedonanorbital shaker for
15 minutes. A MagWell™ magnetic separator was used to
remove the supernatant and wash the beads twice, first with
200 μL of PBST followed by 100 μL of PBST. On the second
wash, the beads were moved to new wells, and 100 μL of
BluePhosmicrowell phosphatase substratewas added to each
well. The plate was protected from light and incubated for
15 minutes. The absorbance of the supernatant was measured
at620or630nm (pLDHdetection).Next, thebeadswerewashed
three times (100 μL PBST) and moved to new wells on the last
washbeforebeing resuspended in100μLTMBOnesolutionand
incubated for 5minutes. The supernatantwas then removedand
the reaction was quenched with 100 μL of 2 M H2SO4. Absor-
bance was measured at 450 nm for detection of HRP2.
Stability study. Dried blood spots were prepared and
stored in Ziploc bags containing the desiccant at room tem-
perature (up to 8 days) and −20C (up to 188 days). At varying
time points, DBSs were removed from storage and analyzed
using the SCSD ELISA for pLDH and HRP2.
Study setting. Patient DBS samples were collected from
theNchelengedistrict of Zambia aspart of a separate study on
parasite clearance rates in children less than 5 years of age
presenting with uncomplicated malaria at a local clinic. These
de-identified samples were made available to the authors for
assessment of pLDH and HRP2 clearance patterns relative to
parasite clearance rates using the DBS SCSD ELISA.
Patient recruitment and ethics.Children at the clinic who
tested positive for malaria (SD Bioline Pf) were recruited for
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this study only if a parent or guardian provided written in-
formed consent. The samples were collected under in-
stitutional review board approval TDRC/C4/09/2014 and
after approval was granted by the Zambian National Health
Research Authority (MH/101/17/6).
Patient samples. Finger-prick blood samples were col-
lected on protein saver 903 cards. At the time of collection,
parasitemia was determined by thick smear microscopy;
parasites were counted per 200 white blood cells (WBC) and
parasite levels were determined using an estimate of 8,000
WBC/μL. Samples were collected between December 2014
and August 2015, stored at −20C, and analyzed by SCSD
ELISA in July 2016. Patients were enrolled in the study and
received treatment with artemether–lumefantrine (Coartem®)
after malaria diagnosis by SDBioline Pf RDT and confirmation
of infection by thick smear. Samples (DBS and thick smears)
were then collected at 15 time points after treatment: 0, 6, 12,
18, 24, 30, 36, 42, and 48 hours as well as 3, 7, 14, 21, 28, and
35 days. Samples for all time points for 15 patients were an-
alyzed in this study.
Patient DBS sample SCSD ELISA. All patient samples
were coded, and the assays were carried out blinded to mi-
croscopy results. Patient DBS samples were extracted and
analyzed via the SCSDELISA as described previouslywith the
following exceptions: 1) the standard curve (0–400 parasites/μL
from 18,450 parasites/μL stock: 0–520 pM pLDH, 0–680 pM
HRP2) consisted of 1:19 (v:v) parasitized whole blood diluted
in PBST, mimicking the matrix of DBS extract, and 2) if the
signal for either pLDH or HRP2 was above the linear range of
the assay, the DBS extract was reanalyzed at the appropriate
dilution.
Data analysis. Biomarker concentrations in DBS extracts
were interpolated from best fits of linear standard curves. All
error bars shown are the standard error of measurement.
Limits of detection were calculated as the biomarker
concentration at sblank + 3SDblank. Intra-assay variation (%CV)
was determined as the average relative standard deviation
of triplicate measurements on a single plate. Inter-assay
variation (%CV) was determined by finding the standard
deviation of all measurements at a given concentration on
different days and dividing by the average absorbance mea-
surement at that concentration. For analysis of clearance
rates across all patients, biomarker concentrations were
normalized to their highest value across all time points for
each patient.
RESULTS AND DISCUSSION
Dried blood spot SCSDELISA optimization. The protocol
for the DBS sample SCSD ELISA was optimized systemati-
cally. Optimum conditions for HRP2 recovery from DBS were
previously reported.16 To determine whether this method
achieved sufficient elution of pLDH, the recoveries of both
biomarkerswere comparedacrossmultiple extraction times in
PBST. The pLDH extraction efficiencies were not significantly
different from those of HRP2 across all DBS extraction in-
cubation times. In addition, increasing time did not result in
significant differences in recoveries for either biomarkers
(Supplemental Figure 1).
Once the DBS samples were extracted, the eluents were
filtered to reduce nonspecific signal due to bead aggregation
around small fibers and pieces of paper. To accomplish this,
we developed an affordable, homemade filtering device that
could be used in low-resource settings (Figure 1A). The filter
consisted of a 96-well PCR plate with the tips of the tubes cut
off. Cheap, commercially available nylon fabric covered the
open bottoms of the PCR plate, which nested directly into a
flat-bottomed 96-well plate. The nylon fabric was discarded
after all samples and standards were filtered into the flat-
bottomed plate, and the PCR plate was washed in 10%
FIGURE 1. (A) Affordable 96-well plate filter for use in low-resource settings. (B) Filtering improved the performance of both the Plasmodium
lactate dehydrogenase (pLDH) and Plasmodium falciparum histidine-rich protein 2 (HRP2) portions of the dried blood spot simultaneous capture
and sequential detection ELISA. This figure appears in color at www.ajtmh.org.
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bleach, followed by three washes with deionized water, and
reused with fresh nylon fabric for filtering. The total cost of the
filtering devicewas $0.10/sample, but recycling the PCRplate
decreased filtering costs to as low as $0.012/sample. As
shown in Figure 1B, filtering DBS extracts through this device
reduced nonspecific background signal by 4-fold for pLDH
and 1.5 times for HRP2, increasing the signal-to-noise ratio
from1.6 to 3.2 and 3.3 to 4.5, respectively. In addition, filtering
the samples had the benefit of decreasing the variation be-
tween repeated measurements for the pLDH portion of the
assay (F test, P = 0.02).
After filtration, the SCSD ELISA was performed on DBS
extracts. The previously reported protocol was performed
directly in lysed whole blood.19 Because DBS extracts are
more dilute than lysed whole blood, blocking conditions for
the assay had to be re-optimized. It was found that adding an
equal volume of 10% nonfat dried milk to DBS extracts
resulted in the highest signal-to-noise ratio (Supplemental
Figure 2A). Magnetic bead volumes and detection antibody
concentrations used in the SCSD ELISA for pLDH and HRP2
were screened in this new matrix, and it was found that the
optimized conditions for these parameters were identical to
those in the original protocol for both biomarkers (Supplemental
Figure 2B and C).
Dried blood spot SCSD ELISA performance. The per-
formance of the DBS SCSD ELISA protocol was evaluated
usingDBSmade fromparasitizedwhole blood. The assaywas
performed in triplicate once per day for 3 days (Figure 2). The
linear range of the assay was found to be 0.6–18 nM for pLDH
and 0.15–9.5 nM for HRP2. The intra-assay variation was
10.5% for pLDH and 4.7% for HRP2. The inter-assay variation
was 12.5% for pLDH and 16.9% for HRP2. All four %CV val-
ues demonstrate acceptable reproducibility. The limits of
detection were 600 ± 500 pM pLDH and 69 ± 30 pM HRP2,
corresponding to 150 and 24 parasites/μL in our in-house
culture, respectively. It is important to note that these lower
limits are reported as the biomarker concentrations in the
original whole blood sample that was spotted onto the DBS
card. Thus, the inherent dilution associated with DBS ex-
traction and DBS extraction efficiency are taken into account.
Although intended for laboratory use, the performance of the
DBS SCSD ELISA was equal to or better than that of currently
available malaria rapid diagnostic tests.
Biomarker detectability over time.Dried blood spot cards
are designed for long-term storage and preservation of bi-
ological samples. However, it has been shown that biomarker
detectability from DBS changes over time.16,25 Thus, we
measured pLDH andHRP2 signals from negative and positive
(0 and 1,000 parasites/μL) DBS stored at both −20C and
room temperature over time. As shown in Supplemental
Figure 3, neither pLDH nor HRP2 signal significantly changed
after 6 months of storage at –20C. However, for both bio-
markers, recovery dramatically dropped over time when
stored at room temperature. The pLDH signal at day 8 was
reduced to 35% of the signal on day 0 and HRP2 signal was
reduced to 31% in the same timeperiod. This signal loss could
be due to protein breakdown and loss of structure over time or
to reduced extraction efficiency off the DBS card.
PatientDBSsamples fromrural Zambia.Driedblood spot
samples were collected over 15 time points after treatment of
15 patients; in total, 225 DBSs were analyzed for this study.
Parasitemias at each time point were determined by micros-
copy at the time of collection. Because DBS patient samples
were1–2yearsoldwhenanalyzed, itwasnot assumed that the
extraction efficiency of these patient samples would be the
same as that of freshly prepared DBS standards. Thus, rather
than comparing patient DBS to a standard curve of freshly
prepared DBS to determine biomarker concentrations in the
original whole blood sample that was spotted onto the card,
biomarker concentrations in extracts were determined. This
was performed at Macha Research Trust using standard
curves in parasitized whole blood diluted 1:19, approximating
the DBS extract matrix. Several assays were performed each
day over the course of 2 weeks (N = 14). The intra-assay var-
iation was 9.2% for pLDH and 6.1% for HRP2 and the inter-
assay variation was 19.2% and 24.5% for pLDH and HRP2,
respectively. Linear ranges for the assay were 10–520 pM
pLDH and 10–680 pM HRP2. The limit of detection for the
pLDH portion of the assay was 9 ± 6 pM, corresponding to six
parasites/μL in our in-house culture. The detection limit for
HRP2 was 7 ± 6 pM, which corresponds to four parasites/μL.
These detection limits were used as cutoff values for de-
termination of positive patient samples.
The relationships between biomarker concentrations and
parasite levels for both pLDH and HRP2 based on all DBS
patient samples analyzed in this study are shown in Figure 3.
Similar to previous reports, HRP2concentrationswere several
orders of magnitude higher than pLDH concentrations.26
Weak-to-moderate, but significant (P < 0.001), positive cor-
relationswith parasitemia were observed for both biomarkers.
The Spearman correlation coefficient was 0.36 (0.23–0.47) for
pLDH and parasitemia and 0.46 (0.36–0.57) for HRP2 and
FIGURE 2. Standard curves for dried blood spot on-bead simultaneous capture and sequential detection ELISA for (A) Plasmodium lactate
dehydrogenase (pLDH) and (B) histidine-rich protein 2 (HRP2).
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parasitemia, demonstrating the utility of these biomarkers for
malaria diagnosis. The nonparametric Spearman correlation
coefficient was chosen because the parasite densities and
concentrations measured do not follow normal distributions
(D’Agostino and Pearson normality tests, P < 0.001). For
pLDH, direct correlations with parasitemia have been dem-
onstrated in the literature for both P. falciparum and Plasmo-
dium vivax malaria.26–28 The strength of the correlation found
in this study is lower than that in some reports, possibly be-
cause of the lack of controlled DBS storage conditions after
sample collection. Previous reports have shown that un-
controlled DBS storage can lead to reduced pLDH recovery in
mock patient samples.25 Similarly, we found that DBS storage
at room temperature resulted in a drastic reduction of pLDH
detectability, potentially explaining why DBS from seven pa-
tients with high initial parasitemia had initial pLDH levels near
or below thedetection limit of theDBSSCSDELISA.However,
biological factors, such as parasite life cycle stage, also affect
pLDH expression, potentially influencing the strength of the
observed correlation.29
Many studies have shown correlation between HRP2 and
parasitemia, although some have found no correlation.16,26,30
While uncontrolled storage conditions have a similar detri-
mental impact onHRP2 detectability as for pLDH, initial HRP2
concentrations were detectable for all patients in this study.
However, HRP2 expression has been shown to vary with
parasite stage and strain.31,32 In addition, the duration of in-
fection and persistence of HRP2 in circulation, addressed in
detail in the next section, likely influenced the strength of the
correlation between biomarker concentration and parasite
density.
Biomarker clearance. Unique parasite and biomarker
clearance patterns were observed for each patient. Figure 4
shows clearance rates for three representative patients and
Supplemental Figure 4 shows clearance rates for the
remaining 12 patients. Overall, for the 15 patients in this
study, the median parasite clearance time by microscopy
after treatment with artemether–lumefantrine was 30 hours
(interquartile range: 24–36 hours). Clearance times for the
biomarkerswere determinedas the first timepoint inwhich the
biomarker was undetectable for that time point and all sub-
sequent time point measurements. The median pLDH clear-
ance time was 36 hours (interquartile range: 6–72 hours) after
treatment, following closely with parasite clearance time. In
contrast, 13 of the 15 patients (87%) had measurable HRP2
levels at the final time point of this study (35–52 days after
treatment). It should be noted that five of the 13 patients (38%)
who were HRP2 positive at the last time point had undetect-
able HRP2 levels at least once at a previous time point. It is
possible that uncontrolled storage conditions may have
contributed to the undetectable HRP2 levels in the earlier time
points. However, for one patient, pLDH levels also increased
at the final time point, indicating possible reinfection or re-
crudescence (Supplemental Table 1, Patient 30).
The relationship between intensity of infection and bio-
marker persistence was also investigated. Patient infection
levels were classified based on initial parasitemias: low
(0–14,999 parasites/μL, N = 7), medium (15,000–74,999 par-
asites/μL,N=5), andhigh (³75,000parasites/μL,N=3).Using
a one-way ANOVA (df = 12), there were no significant differ-
ences in parasite clearance time (P = 0.4221), pLDH clearance
time (P = 0.5543), or HRP2 clearance time (P = 0.3206) across
all three groups.
The overall clearance patterns for all patients are repre-
sented in Figure 5. For each patient, parasite and biomarker
levels were normalized to the highest concentration mea-
sured. The average across all patients at each time point was
calculated and plotted, allowing for a clear visualization of
the overall parasite, pLDH, and HRP2 clearance patterns in
this study. In general, pLDH became undetectable before
infections became submicroscopic. In contrast, HRP2
remained in circulation for the duration of the study, de-
creasing in concentration slowly over time. The persistence
and accumulation of HRP2 in circulation over the duration of
an infection likely explain why HRP2 concentrations were
significantly higher than pLDH concentrations for all patients
in this study.
In the context of malaria elimination, an ideal evaluation tool
would be positive when a patient has an active infection and
negative in the absence of parasites. Distinguishing between
falciparum and non-falciparum infections would also be clini-
cally useful and inform treatment and provide useful epide-
miological data. A sensitive dual pLDH and HRP2 detection
method could fulfill these ideals; however, this work highlights
the challenges of developing a dual assay. Although pLDH
detection could overcome the lack of specificity of HRP2 that
results from persistence in host circulation after parasite
FIGURE 3. Correlations between (A) Plasmodium lactate de-
hydrogenase (pLDH) and parasitemia and (B) histidine-rich protein 2
(HRP2) and parasitemia in patient samples from rural Zambia. Weak
correlations between biomarker concentrations and parasite burdens
were observed. Note: for many data points, error bars are smaller than
the size of the symbol representing the mean value.
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clearance, the relatively low levels of circulating pLDH mean
that active infections could bemissed in the dual format. Such
a result would undermine malaria elimination efforts, allowing
active infections to persist and contribute to transmission.
In contrast, an HRP2-only diagnostic could result in over-
diagnosis and treatment, potentially resulting in unnecessary
costs and a failure to treat other serious illnesses. Thus, there
is a pressing need to develop more sensitive molecular rec-
ognition elements and detection methods for pLDH.
The previously developed SCSD ELISA fills this need and is
an order of magnitude more sensitive than commercially
available ELISA kits for both pLDH and HRP2.19 Here, the
assay was adapted for detection of both biomarkers from a
single DBS. Uncontrolled DBS storage conditions and the
inherent dilution when DBSs are extracted into buffer con-
tributed to reducedanalytical sensitivity of the assay, although
detection limits of theDBSSCSDELISA remain comparable to
that of commercially available ELISA kits for pLDH and HRP2
applied to whole blood samples. In contrast to commercially
available ELISA kits, which are singleplex and take 3–6 hours
to complete, the SCSD ELISA is capable of detecting two
biomarkers from a single DBS in less than 1 hour. In addition,
the ease with which the antibody-functionalized beads were
transported to Zambia and the possibility of lyophilizing the
beads for stable ambient storage could allow the developed
assay to be applied in laboratories in low-resource settings.
Thus, the DBS SCSD ELISA has the potential to increase the
throughput and information yield of large epidemiological or
surveillance studies based on DBS samples. To this end, we
have demonstrated the utility of this assay for the evaluation of
biomarker clearance in a patient population from rural Zambia.
In the future, the DBS SCSD ELISA will be useful for the
characterization of clearance patterns in other populations
and could also serve as a rapid, preliminary screening tool for
parasites with pfhrp2 deletions.
CONCLUSION
In this work, the on-bead SCSD ELISA for pLDH and HRP2
was adapted for use with DBS samples. For mock DBS sam-
ples, the assaywas highly reproducible and could detect pLDH
as low as 600 ± 500 pM and HRP2 as low as 69 ± 30 pM,
corresponding to 150 and 24 parasites/μL in our in-house
culture, respectively. Using the DBS SCSD ELISA, we dem-
onstrated the need for controlledDBSstorage; the detectability
of both pLDH andHRP2 fromDBS decreased nearly 70%after
FIGURE 4. Biomarker clearance trends for three representative patients collected over 35 days.Plasmodium lactate dehydrogenase (pLDH) (top,
solid) and histidine-rich protein 2 (HRP2) (bottom, solid) in dried blood spot extract and parasitemia (dashed) are plotted against time for (A) Patient
29, (B) Patient 55, and (C) Patient 58.
FIGURE 5. Normalized parasite, Plasmodium lactate dehydrogenase (pLDH), and histidine-rich protein 2 (HRP2) clearance patterns plotted over
time.
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8 days of storage at room temperature. Next, we applied the
DBS SCSD ELISA to patient DBS samples from rural Zambia
to measure pLDH and HRP2. In these samples, weak-to-
moderate correlations between biomarker concentration and
parasitedensitywere found forbothbiomarkers, and theoverall
concentrations of HRP2 were several orders of magnitude
higher than those of pLDH. Finally, biomarker clearance pat-
terns relative to parasite clearance were studied. It was found
that pLDH clearance followed closely with parasite clearance,
whereas 87% of patients had detectable levels of HRP2 for
35–52 days after treatment. This work demonstrated the utility
of the SCSD ELISA for quantifying pLDH and HRP2 from DBS
samples and its potential for future application in epidemio-
logical studies.
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